Beginnings Reporting on science and intelligent design

Racing to stop coronavirus

Science | Researchers experiment with altering current medications to respond to the rapidly spreading disease
by Julie Borg
Posted 2/20/20, 01:12 pm

When the Ebola epidemic struck West Africa in 2014, drugmakers had been working on a vaccine for the virus for 10 years. But it took more than a year to get it to affected areas.

“That vaccine was shown to be 100 percent effective, suggesting that much of the epidemic could have been prevented,” according to the Coalition for Epidemic Preparedness Innovations, which formed in 2017 to try to prevent the Ebola failure from happening again. The coronavirus outbreak is the first major test of the organization’s resources.

“We are making very aggressive efforts in the hopes of having a vaccine available—some form of vaccine available, potentially, as early as this fall,” said Richard Hatchett, CEO of the coalition.

The new coronavirus, also known as COVID-19, started in China in December and has spread to more than two dozen countries. About 75,000 people have fallen ill, and about 2,100 have died, mostly in China. While some scientists race to develop a vaccine against the virus, others are working on a treatment for those who are already sick.

Scientists in China are testing a repurposed, experimental antiviral to treat coronavirus. Gilead, a U.S. biotechnology company, designed the drug remdesivir to fight similar infectious diseases like Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). No experiments have proven remdesivir safely or effectively treats the new coronavirus in humans, but “available data in other coronaviruses give us hope,” according to Gilead.

Doctors administered remdesivir to the first U.S. patient to become ill with the virus after his symptoms worsened during hospitalization. The 35-year-old man showed improvement within two days of starting the drug and suffered no adverse side effects, according to the case study published Jan. 31 in The New England Journal of Medicine. Doctors have since discharged him from the hospital.

Another group of researchers reported earlier this month that remdesivir and the anti-malarial drug chloroquine stopped the spread of the virus among human cells in a lab. Low doses of both drugs worked against the virus without being toxic to the human cells. Chinese health regulators also plan to begin human trials of Kaletra, a drug that combines lopinavir and ritonavir and is used to treat HIV, to fight coronavirus.

Meanwhile, other companies and scientists are working on a vaccine. Keith Chappell at the University of Queensland in Australia is building what he calls a “molecular clamp,” which can boost the immune system’s ability to recognize and destroy coronavirus proteins. He told NPR he aims to have a product ready within 16 weeks of getting the virus’s genetic information, which the Chinese made public in early January.

The Pentagon Defense Advanced Research Projects Agency is researching short-term prevention. Using blood samples from coronavirus patients, DARPA scientists are working to isolate the antibodies that fight the virus and inject them into healthcare workers and others in close contact with infected people. Unlike a vaccine, the preventive treatment would only last a few months. Meanwhile, some scientists in China say they found an antibody that binds to the surface of the virus and neutralizes it. They published a preprint of their research on the BioRxiv website on Jan. 28, but it is not peer-reviewed and awaits animal and human testing.

iStock.com/LuCaAr iStock.com/LuCaAr A female brown bear and her cubs

Delayed births

Some pregnant mammals can keep embryos from implanting for days or months until more favorable birthing conditions exist. The process, called diapause, allows a female to hold off having babies if food is scarce, previous offspring are still nursing, or she lacks enough stored fat for a healthy pregnancy.

Many bears breed in the late spring or early summer, but the embryos don’t implant until the mother gains enough weight to sustain them during winter hibernation. Often the implantation does not occur until after she slips into her den for a long winter’s nap.

In a new study, researchers identified the genes that allow diapause. Using drugs and gene-editing techniques, the team learned how to induce the state in embryonic mouse cells.

Their findings in the Jan. 27 edition of Developmental Cell could pave the way for new cancer research. Some cancer cells can go to sleep in the early stages of development and evade chemotherapy drugs. Understanding this process could help scientists arouse dormant cancer cells.

“What if the field could design a therapeutic that could wake cancer cells up at the right time so the drugs don’t miss them?” lead researcher Asis Hussein asked. —J.B.

Associated Press/Photo by Cliff Owen (file) Associated Press/Photo by Cliff Owen (file) A biologist works with serum samples containing Ebola antibodies at the National Institutes of Health in Bethesda, Md.

Deadly virus may save lives

Scientists at Yale University recently experimented with an unusual way of fighting brain cancer by using genes from the deadly Ebola virus. The researchers modified a virus to contain an Ebola gene that helps it evade the immune system. Then they injected the modified virus into the brains of mice with glioblastoma, one of the hardest to treat and most lethal forms of brain cancer. Results, published Feb. 12 in the Journal of Virology, showed the modified virus targeted and eliminated some of the cancerous tumors and increased the survival time of the mice.

Cancer researchers have long tried to find a way to combat cancer with viruses. Most cancer cells can’t fight off viruses, but the body’s immune system still can and does, limiting the treatments’ effectiveness. The Ebola gene allows the virus to hide from the body’s immune response and wage a stealthy attack on the tumor. —J.B.

iStock.com/jnerad iStock.com/jnerad A duck-billed dinosaur footprint

Dinosaur disease

Researchers at Tel Aviv University in Israel discovered evidence of a rare and sometimes painful childhood disease in the fossilized tail section of a young duck-billed dinosaur that once roamed the prairies of southern Alberta, Canada.

Langerhans cell histiocytosis (LCH) afflicts mainly children younger than 10 with tumors that appear suddenly in their bones. It can produce pain, but the tumors often disappear without intervention. In the study, published on Feb. 10 in Scientific Reports, the researchers used new, high-resolution imaging to identify the disease in the fossil by analyzing two large cavities caused by tumors.

The scientists hope the discovery will uncover how diseases like LCH manifest themselves in different species and help researchers find new and effective treatments, said Israel Hershkovitz, a professor of anatomy and anthropology at Tel Aviv. —J.B.

Julie Borg

Julie is a clinical psychologist and writer who lives in Dayton, Ohio. She reports on science and intelligent design for WORLD Magazine and WORLD Digital.

Read more from this writer
ADVERTISEMENT